Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (283)	10/18/2003 5:11:37 AM
From: mopgcw	Respond to of 590

I agree. If all firing on all cylinders, abgx would be able to get a better deal.

To: Miljenko Zuanic who wrote (283)	10/20/2003 10:43:18 AM
From: fred hayes	Read Replies (1) \| Respond to of 590

Miljenko: >Sure that 100M is enough for ABGX work, on AZ's targets< Catching up after long "vacation" from thinking about stocks. Just read the releases about the AZ deal, and it looked to me like AZ would pay for ABGX pre-clinical work on AZ targets. My impression is the $100M is not dedicated to the AZ work, and that the risk on ABGX has been reduced, not increased, because AZ is paying the full cost of developing their targets. fred